Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Tikun Olam Cannbit Pharmaceuticals's enterprise value is $1.66 Mil.
Tikun Olam Cannbit Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.75 Mil. Therefore, Tikun Olam Cannbit Pharmaceuticals's EV-to-EBITDA for today is -2.23.
TKUNF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -15.19 Med: -4.29 Max: 15.65
Current: -2.26
During the past 13 years, the highest EV-to-EBITDA of Tikun Olam Cannbit Pharmaceuticals was 15.65. The lowest was -15.19. And the median was -4.29.
TKUNF's EV-to-EBITDA is ranked worse than 100% of 735
companies
in the Drug Manufacturers industry
Industry Median: 13.3
vs TKUNF: -2.26
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Tikun Olam Cannbit Pharmaceuticals (OTCPK:TKUNF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Tikun Olam Cannbit Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Tikun Olam Cannbit Pharmaceuticals's share price for today is $6.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tikun Olam Cannbit Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-6.310.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tikun Olam Cannbit Pharmaceuticals EV-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Tikun Olam Cannbit Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tikun Olam Cannbit Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tikun Olam Cannbit Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Tikun Olam Cannbit Pharmaceuticals's EV-to-EBITDA falls into.
Tikun Olam Cannbit Pharmaceuticals's current Enterprise Value is $1.66 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tikun Olam Cannbit Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tikun Olam Cannbit Pharmaceuticals (TKUNF) has a EV-to-EBITDA of -2.23 as of Aug. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Tikun Olam Cannbit Pharmaceuticals. According to the industry distribution chart, Tikun Olam Cannbit Pharmaceuticals ranks #999999 out of 735 companies in the Drug Manufacturers industry.
Is Tikun Olam Cannbit Pharmaceuticals' EV-to-EBITDA too high?
Tikun Olam Cannbit Pharmaceuticals' current EV-to-EBITDA is -2.23. Based on the distribution chart, Tikun Olam Cannbit Pharmaceuticals ranks #999999 out of 735 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Tikun Olam Cannbit Pharmaceuticals has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Tikun Olam Cannbit Pharmaceuticals' EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Tikun Olam Cannbit Pharmaceuticals ranks #999999 out of 735 companies for EV-to-EBITDA. This places Tikun Olam Cannbit Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 13.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.30, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Tikun Olam Cannbit Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tikun Olam Cannbit Pharmaceuticals's current EV-to-EBITDA is -2.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tikun Olam Cannbit Pharmaceuticals stock overvalued right now?
Tikun Olam Cannbit Pharmaceuticals (TKUNF) has a current EV-to-EBITDA of -2.23. The stock's GF Value™ is $26.54, compared to a current price of $6.00 — trading 77.4% below its estimated fair value. The current EV-to-EBITDA is -2.23. Tikun Olam Cannbit Pharmaceuticals' overall GF Score™ is 8/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Tikun Olam Cannbit Pharmaceuticals (TKUNF), the current EV-to-EBITDA is -2.23 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tikun Olam Cannbit Pharmaceuticals (TKUNF) Overvalued in 2026?
Based on GuruFocus' analysis, Tikun Olam Cannbit Pharmaceuticals stock appears to be undervalued.
The current stock price of $6.00 is trading 77.4% below its estimated GF Value™ of $26.54.
Key valuation signals for TKUNF:
EV-to-EBITDA: -2.23
GF Value™: $26.54 vs. price of $6.00 (77.4% below fair value)
No single metric tells the full story. See the TKUNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TKUNF has been successfully added to your 
